High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China
- 1Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
- 2Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China
- 3Tsinghua-Peking Center for Life Sciences, Beijing, China
- 4Department of Infectious Diseases, JinYin-tan Hospital, Wuhan, China
- 5Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China
- 6Medial Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
A Corrigendum on
High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China
By Cao W, Liu XS, Hong K, Ma ZY, Zhang YL, Lin L, et al. (2021). doi: 10.3389/fimmu.2021.627844
Error in Table
In the original article, there was a mistake in Table 1 as published. The author identified the calculating errors in the percentage of comorbidity, symptoms, and treatment. The corrected Table 1 appears below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: COVID-19, high-dose intravenous immunoglobulin, immunomodulation, 28-day mortality, inflammatory markers
Citation: Cao W, Liu X, Hong K, Ma Z, Zhang Y, Lin L, Han Y, Xiong Y, Liu Z, Ruan L and Li T (2021) Corrigendum: High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China. Front. Immunol. 12:671443. doi: 10.3389/fimmu.2021.671443
Received: 23 February 2021; Accepted: 04 March 2021;
Published: 22 March 2021.
Edited and reviewed by: Christoph T. Berger, University of Basel, Switzerland
Copyright © 2021 Cao, Liu, Hong, Ma, Zhang, Lin, Han, Xiong, Liu, Ruan and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Taisheng Li, litsh@263.net
†These authors have contributed equally to this work